Connect Biopharma Holdings Ltd (CNTB) stock
CNTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.58−0.06 (-9.98%)
Close on Nov 17, 2026Market cap $36.45MP/E –Yield –
Connect Biopharma r&d expenses
Research and development expenses are spending on new products and technology.
Connect Biopharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $53.70M, up 75.2% year over year. For fiscal 2025 it was $37.80M, up 29.2% from the year before. The highest annual figure on record is $96.63M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.80M | +29.2% |
| FY2024 | Dec 31, 2024 | $29.26M | -44.8% |
| FY2023 | Dec 31, 2023 | $53.00M | -45.1% |
| FY2022 | Dec 31, 2022 | $96.63M | +20.0% |
| FY2021 | Dec 31, 2021 | $80.50M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $16.27M | +85.5% |
| Q1 FY2026 | Mar 31, 2026 | $15.03M | +126.6% |
| Q4 FY2025 | Dec 31, 2025 | $11.28M | +80.9% |
| Q3 FY2025 | Sep 30, 2025 | $11.11M | +23.3% |
| Q2 FY2025 | Jun 30, 2025 | $8.77M | +64.0% |
| Q1 FY2025 | Mar 31, 2025 | $6.63M | -23.4% |
| Q4 FY2024 | Dec 31, 2024 | $6.24M | – |
| Q3 FY2024 | Sep 30, 2024 | $9.01M | – |
| Q2 FY2024 | Jun 30, 2024 | $5.35M | – |
| Q1 FY2024 | Mar 31, 2024 | $8.66M | – |
See a number that looks wrong?